Kahn SE, Cooper ME, Del Prato S
Post-surgical or post-injury patients in rebuilding phases where lean tissue preservation is important
Since TRPV1 and ASIC1 levels are elevated in diabetic rats, MTZs suppressive influence on these levels may be one of the pharmacological mechanisms behind the drugs therapeutic effects against diabetes-induced hyperalgesia (Bektur et al
A peptide credited with somnogenic, analgesic, anti-stress, endocrine, and anti-withdrawal actions, with no receptor and no established pathway linking any of them, is a peptide whose reported activity has never been localized
Apitegromab: Phase 3 SAPPHIRE in SMA# The Phase 3 SAPPHIRE trial represents the most advanced clinical success for any myostatin-targeted therapy: 188 patients aged 2-21 with Type 2 or 3 SMA, all receiving background SMN-targeted treatment Primary endpoint met : Clinically meaningful improvement on HFMSE (Hammersmith Functional Motor Scale Expanded) versus placebo (p=0.0192), with a mean difference of 1.8 points Functional responders : 30.4% of apitegromab patients achieved 3 or more point HFMSE improvement versus 12.5% placebo Upper limb function : Consistent improvement measured by RULM (Revised Upper Limb Module) Published in The Lancet Neurology This is notable because it overcomes the historical "mass-function disconnect" that plagued earlier myostatin inhibitors -- apitegromab improved actual motor function, not just muscle mass
